2023
Estimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool
Leone J, Graham N, Leone J, Tolaney S, Leone B, Freedman R, Hassett M, Vallejo C, Winer E, Lin N, Tayob N. Estimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool. European Journal Of Cancer 2023, 189: 112930. PMID: 37356327, DOI: 10.1016/j.ejca.2023.05.018.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityTriple-negative breast cancerRisk of BCSMTumor characteristicsBreast cancerCumulative riskNon-metastatic triple-negative breast cancerMost tumor characteristicsCancer-specific mortalityRisk of deathPopulation-based riskHigh-grade triple-negative breast cancerCause mortalityMost patientsPathologic variablesInitial diagnosisHigh riskNew diagnosisPatientsMortalityDiagnosisYear 0RiskCancerWomen
2022
Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool
Leone JP, Graham N, Tolaney SM, Leone BA, Freedman RA, Hassett MJ, Leone J, Vallejo CT, Winer EP, Lin NU, Tayob N. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool. European Journal Of Cancer 2022, 173: 20-29. PMID: 35841843, DOI: 10.1016/j.ejca.2022.06.029.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityHR-positive breast cancerBreast cancerCumulative riskCause mortalityTumor characteristicsRisk of BCSMHormone receptor-positive breast cancerReceptor-positive breast cancerCancer-specific mortalityEnd Results registryLong-term mortalityRisk of deathCancer patient subgroupsPopulation-based riskPathologic variablesInitial diagnosisPatient subgroupsSEER dataPatientsAge groupsCancerMortalityHormone receptorsDiagnosis
2021
Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry
Leone JP, Leone BA, Tayob N, Hassett MJ, Leone J, Freedman RA, Tolaney SM, Winer EP, Vallejo CT, Lin NU. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Research And Treatment 2021, 187: 843-852. PMID: 33590387, DOI: 10.1007/s10549-021-06121-x.Peer-Reviewed Original ResearchConceptsRisk of BCSMBreast cancer-specific mortalityStage III breast cancerHR-negative diseaseHR-positive diseaseCancer-specific mortalityBreast cancerLate deathsNodal statusTumor sizeUnknown hormone receptor statusHR-positive tumorsEnd Results registryHormone receptor statusEnd Results (SEER) dataTraditional clinicopathologic factorsCumulative incidence functionGray regressionMethodsUsing SurveillanceAxillary nodesClinicopathologic factorsReceptor statusStage subgroupsPrimary tumorTumor grade
2019
Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry.
Leone J, Vallejo C, Hassett M, Leone J, Freedman R, Tolaney S, Leone B, Lin N, Winer E. Factors associated with twenty-year (y) risks of breast cancer-specific mortality (BCSM) in the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal Of Clinical Oncology 2019, 37: 540-540. DOI: 10.1200/jco.2019.37.15_suppl.540.Peer-Reviewed Original ResearchRisk of BCSMBreast cancer-specific mortalityHR- breast cancerBreast cancerAdjusted riskCumulative riskAnnual event rateCancer-specific mortalityHormone receptor statusBreast cancer deathsEnd Results registryBetter adjuvant therapyKaplan-Meier analysisLong-term riskLate deathsAdjuvant therapyLate relapseReceptor statusHR statusPrimary cancerCox regressionBaseline variablesBlack raceCancer deathClinical trials